The aforementioned recombinant soluble ACE2 developed for ARDS patients, although promising in alleviating clinical symptoms such as hypoxemia and protecting the lungs, has rather limited efficacy, probably due to its short half-life of ~3 hours in humans (16), resulting in an inability to accumulate sufficient concentrations of the drug at the lesion site. Here, ACE2 is linked to acute respiratory distress syndrome.